- Prognostic value of plasma IgG N-glycome traits in patients with pulmonary 1
- arterial hypertension: an observational cohort study 2
- 3 Running title: Plasma prognostic glycan biomarker for PAH
- Ze-Jian Zhang, PhD^{1#}; Chao Liu, MD^{2#}; Jie-Ling Ma, MD^{2#}; Jing-Si Ma, BS³; Jia 4
- Wang, BS⁴; Ruo-Nan Li, BS³; Dan Lu, MD⁵; Yu-Ping Zhou, MD²; Tian-Yu Lian, 5
- MD¹; Si-Jin Zhang, MD⁶; Jing-Hui Li, MD⁷; Lan Wang, MD⁸; Kai Sun, MD¹; Chun-6
- Yan Cheng, MD^{6*}; Wen-Hui Wu^{8*}; and Zhi-Cheng Jing, MD^{6*} 7
- **Affiliations** 8
- ¹State Key Laboratory of Complex Severe and Rare Diseases, Peking Union Medical 9
- College Hospital, Chinese Academy of Medical Sciences and Peking Union Medical 10
- College, Beijing 100730, China; 11
- 12 ²Department of Cardiology, State Key Laboratory of Complex Severe and Rare
- Diseases, Peking Union Medical College Hospital, Chinese Academy of Medical 13
- Sciences and Peking Union Medical College, Beijing 100730, China; 14
- 15 ³School of Pharmacy, Henan University, Kaifeng 475004, China;
- ⁴Department of Medical Laboratory, Weifang Medical University, Weifang 261053 16
- 17 China;
- ⁵Cardiac Department, Aerospace Center Hospital, Peking University Aerospace School 18
- of Clinical Medicine, Beijing 100049, China; 19
- ⁶Department of Cardiology, Guangdong Institute of Cardiovascular Diseases, 20
- Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 21
- Southern Medical University, Guangzhou 510080, China; 22 NOTE: This preprint reports new research that has not been certified by peer review and should not be used to guide clinical practice.

- 23 ⁷State Key Laboratory of Cardiovascular Disease and FuWai Hospital, Chinese
- Academy of Medical Sciences and Peking Union Medical College, Beijing 100037, 24
- 25 China;
- ⁸Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School 26
- 27 of Medicine, Tongji University, Shanghai 200433, China.
- *These authors contributed equally to this work as co-first authors. 28
- *These authors contributed equally to this study as co-corresponding authors. 29
- **Address for Correspondence:** 30
- 31 Zhi-Cheng Jing, MD, PhD
- Department of Cardiology, Guangdong Institute of Cardiovascular Diseases, 32
- Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 33
- 34 Southern Medical University, No.106, Zhongshan 2nd Road, Guangzhou 510080,
- China. 35
- Tel: +86-13501353191 36
- 37 E-mail: jingzhicheng@vip.163.com
- Wen-Hui Wu, MD 38
- Department of Cardio-Pulmonary Circulation, Shanghai Pulmonary Hospital, School 39
- of Medicine, Tongji University, Shanghai 200433, China, No.507, Zhengmin Road, 40
- 41 Shanghai 200433, China.
- Tel: +86-13917180587 42
- 43 E-mail: wenhui5621006@126.com
- Chun-Yan Cheng, MD 44

- Department of Cardiology, Guangdong Institute of Cardiovascular Diseases, 45
- Guangdong Provincial People's Hospital, Guangdong Academy of Medical Sciences, 46
- Southern Medical University, No.106, Zhongshan 2nd Road, Guangzhou 510080, 47
- China. 48
- 49 Tel: +86-20-83827812
- E-mail: 073047chengchunyan@163.com 50
- **Word Count for main text: 3773** 51

53

54

55

56

57

58

59

60

61

62

63

64

65

66

67

68

69

70

71

72

73

Abstract Background: BNP (brain natriuretic peptide) or NT-proBNP (N-terminal proBNP) is the only blood biomarker in the established risk calculators for pulmonary arterial hypertension (PAH). New plasma biomarkers of systemic origin may improve the risk assessment in PAH. **Methods:** We utilized a robust mass spectrometry-based method to identify prognostic plasma IgG N-glycome traits in PAH patients from two national referral centers in China (Beijing [discovery] cohort, n = 273; Shanghai cohort [validation], n = 349). Then the candidate IgG N-glycan traits were evaluated in combined cohorts adjusted for potential confounders and subgroup analyses. At last, the candidate IgG N-glycan traits were further evaluated against the established prognostic risk equation (three-strata model from the SPAHR and COMPERA analyses) for PAH. The primary endpoint was all-cause mortality. **Results:** IgG Fucosylation was found to predict survival independent of age and sex in the discovery cohort (HR: 0.377, 95% CI: 0.168-0.845, P = 0.018) with confirmation in the validation cohort (HR: 0.264, 95% CI: 0.445-0.751, P = 0.005). IgG Fucosylation remained a robust predictor of mortality in PAH patients in the combined cohorts adjusting for potential confounders and in subgroup analyses based on sex and treatment strategies. Moreover, the addition of the IgG Fucosylation to the established three-strata model significantly improved the predictive accuracy from AUC of 0.67 to AUC of 0.70 (P = 0.043) and IgG Fucosylation was useful in further

stratifying the intermediate risk PAH patients classified by the three-strata model into

- intermediate-low and intermediate-high risk subgroups. 74
- Conclusions: The plasma IgG Fucosylation informs prognosis independent of the 75
- existing clinical assessments in PAH and may be useful in the clinical management of 76
- patients with PAH. 77

- 79 Keywords: IgG N-glycans, pulmonary arterial hypertension, biomarker, prognosis,
- risk stratification, fucosylation 80

Non-standard Abbreviations and Acronyms

6MWD: 6-minute walking distance 82

AUC: area under the curve 83

81

91

NT-proBNP: N-terminal pro-B-type natriuretic peptide 84

PAH: pulmonary arterial hypertension 85

86 PVR: pulmonary vascular resistance

87 RAP: right arterial pressure

ROC: receiver-operating characteristic 88

SvO₂: mixed venous oxygen saturation 89

90 WHO FC: World Health Organization functional class

Clinical Perspective

What is new?

- 94 The plasma IgG Fucosylation, which is in different pathophysiological pathways
- from other established risk factors of pulmonary arterial hypertension (PAH), can 95
- inform prognosis independent of the existing clinical assessments in patients with 96
- PAH. 97

92

93

103

109

- The addition of the IgG Fucosylation to the established three-strata model for PAH 98
- prognosis significantly improved the predictive accuracy. 99
- IgG Fucosylation was useful in further stratifying the intermediate risk PAH 100
- 101 patients classified by the three-strata model into intermediate-high and
- intermediate-low risk subgroups. 102

What are the clinical implications?

- Plasma IgG N-glycan biomarkers may provide a refined risk stratification in PAH 104
- used in combination with the established risk factors. 105
- 106 IgG Fucosylation involved in inflammatory pathways may not only be a promising
- prognostic biomarker but also a potential novel therapeutic target, distinct from 107
- existing targets, for patients with PAH. 108

Introduction

110

111

112

113

114

115

116

117

118

119

120

121

122

123

124

125

126

127

128

129

130

131

Pulmonary arterial hypertension (PAH) represents a rare and malignant cardiopulmonary condition characterized by dysregulation of endothelium-derived vasoactive factors, inflammatory processes, and obstructive remodeling of small pulmonary arteries. These pathological changes lead to a progressive increase in pulmonary vascular resistance (PVR) and mean pulmonary artery pressure, culminating in right heart failure and, ultimately, death for the majority of affected patients.^{1,2} The prognosis of PAH remains poor with an estimated 5-year survival rate of 60% for patients with advanced PAH.³⁻⁵ Nevertheless, treatment response varies between patients due to the heterogeneity of the disease, ⁶ and life expectancy is quite variable. Risk stratification and regular assessment of disease severity are vital to guide the clinical management of patients with PAH.^{1,2} The existing guidelines recommend multiparametric risk calculators based on clinical assessment, right ventricular function, exercise, and hemodynamic variables to inform prognosis and guide treatment decision-making in PAH.^{1,2} However, the multidimensional approach suffers from some disadvantages and limitations, such as not all these measurements available at each patient visit, some factors obtained invasively, unsatisfied accuracy, and restricted mechanisms reflected by the parameters. Moreover, in the established multifactorial prognostic model, the circulating biomarker includes only BNP (brain natriuretic peptide) or NT-proBNP (N-terminal proBNP). Abnormal immune

133

134

135

136

137

138

139

140

141

142

143

144

145

146

147

148

149

150

151

152

153

regulation and inflammation have been recognized as critical contributors to the pathogenesis of PAH.⁷⁻⁹ New plasma biomarkers of systemic origin reflecting different components of the pathophysiology of PAH such as immune dysregulation and inflammation may improve the risk assessment of PAH and provide a more sensitive measure of disease severity and therapeutic response. Glycosylation is a prevalent and important post-translational modification that modulates a variety of biological functions. 10,11 Abnormal glycosylation of proteins is thought to play a role in almost every major disease. 12,13 IgG, the predominant glycoprotein and antibody in human biofluids, is a key effector of the humoral immune system and has multiple roles in maintaining the balance of inflammation at the systemic level. 14 The conserved N-linked glycans bound to the unique glycosylation site Asn297 in the Fc domain of IgG are of the complex biantennary type. 15,16 The N-glycan compositions on IgG, particularly the core fucose moiety and the terminal galactose or sialic acids, exhibit variability and hold pivotal roles in regulating IgG structural stability and functional activity, which influences the outcome of the immune response (e.g., antibody's effector functions).¹⁷ For example, it has been widely acknowledged that decreased levels of IgG core fucose contribute to increased antibody-dependent cellular cytotoxicity (ADCC) and inflammation. 18-21 IgG loss of terminal galactose could trigger a proinflammatory response. ^{22,23} It is noteworthy that our team has previously demonstrated dysregulation of the plasma IgG N-glycome in patients with chronic thromboembolic pulmonary hypertension²⁴

and the identified abnormal IgG N-glycan traits may play a crucial role in the pathogenesis and progression of this condition.²⁴ Nevertheless, the glycosylation characteristics of IgG and their prognostic value in patients with PAH have not yet been explored.

The main objective of this study was to identify and validate plasma IgG N-glycan traits that predict survival in patients with PAH to improve risk stratification.

Methods

Study population

From October 2006 to December 2019, all consecutive patients with a definite diagnosis of idiopathic PAH or heritable PAH at two national pulmonary hypertension referral centres (Shanghai Pulmonary Hospital with patients mainly from South China and FuWai Hospital in Beijing with patients mainly from North China) were included in this study. Idiopathic PAH was diagnosed based on baseline right heart catheterization confirming newly diagnosed precapillary pulmonary hypertension, defined by a resting mean pulmonary artery pressure≥25 mmHg, pulmonary artery wedge pressure≤15 mmHg, and PVR>3 Wood units, in the absence of other known causes of PAH. Patients with PAH were diagnosed with heritable PAH if their first or second-degree relatives had a confirmed PAH diagnosis or died from a PAH-like syndrome. The ethics review boards of Shanghai Pulmonary Hospital and FuWai Hospital approved the protocols. Written informed consent was obtained from all

patients. This study complied with the principles of the Declaration of Helsinki.

Baseline blood samples, data collection, and follow-up

Baseline demographic and clinical characteristics, including World Health Organization functional class (WHO FC), 6-minute walking distance (6MWD), and invasive haemodynamics including right arterial pressure (RAP), mean pulmonary artery pressure, pulmonary artery wedge pressure, cardiac index, PVR, and mixed venous oxygen saturation (SvO₂) were collected. Baseline venous plasma for IgG N-glycome profiling and haemodynamic data were obtained during the first diagnostic right heart catheterization. Follow-ups were carried out through clinic visits or phone or internet interviews, and the patient's survival time was calculated by months from the initial PAH diagnosis date to January 2023 or the latest contact date. The primary clinical endpoint was all-cause mortality.

Mass spectrometric IgG N-glycome profiling

The profiling of IgG N-glycome was carried out using matrix-assisted laser desorption/ionization time-of-flight mass spectrometry, ²⁵⁻²⁷ with raw mass spectrometry data processing performed according to established methods outlined in previous reports. ²⁵⁻²⁷ Detailed procedures are provided in the Supplementary Material for reference.

To combine the effects of individual detected N-glycan traits sharing similar

199

200

201

202

203

204

205

206

207

208

209

210

211

212

213

214

215

216

217

218

219

structures and better interpret the biological effects of IgG N-glycosylation, ^{28,29} derived (calculated) N-glycan traits representing the most important features of IgG N-glycosylation including Galactosylation, Bisecting N-acetylglucosamine, and Fucosylation were calculated from the directly detected N-glycans. The formulas used for the calculation: Galactosylation = H3N4F1/(H4N4F1 + 2*H5N4F1); Bisecting Nacetylglucosamine = H3N5F1 + H4N5F1 + H5N5F1; Fucosylation = H3N4F1 + H4N4F1 + H3N5F1 + H5N4F1 + H4N5F1 + H5N5F1 (H = hexose; N = Nacetylhexosamine; F = deoxyhexose [fucose]). 24,27 GlycoWorkbench software (version 1.1.3480) was used to annotate the N-glycan structures. Statistical analysis Normality was determined using the Kolmogorov-Smirnov test. Continuous variables were presented as mean \pm SD for normally distributed data, and as median (interquartile range, 25% to 75%) for non-normally distributed variables. Categorical variables were presented as n (%). Statistical analysis was performed with Statistic Package for Social Science (SPSS Inc., Chicago, USA) version 22.0 and GraphPad Prism version 8.0.0 for Windows (GraphPad Software, San Diego, California USA, www.graphpad.com). All tests were two-tailed with a value of P<0.05 considered statistically significant. Prognostic IgG N-glycan traits were identified by Cox regression analysis corrected for age and sex in the discovery cohort and confirmed in the validation cohort. To

221

222

223

224

225

226

227

228

229

230

231

232

233

234

235

236

237

238

239

240

241

assess whether the prognostic IgG N-glycan trait screened out was an independent prognostic factor, Cox regression analysis adjusted for potential confounders including age, sex, type of PAH, treatment strategies, 6MWD, WHO FC, NT-proBNP, RAP, SvO₂, and cardiac index were conducted. Further adjusted Cox regression analyses were conducted in subgroups stratified by sex and therapeutic strategies. To assess the added value of IgG N-glycan traits to the established risk model, we compared the prognostic accuracy of the three-strata model (the established prognostic risk equation derived from the SPAHR and the COMPERA registry)^{30,31} with that of the IgG N-glycan + three-strata model using receiver-operating characteristic (ROC) analysis. Additionally, IgG N-glycans were employed to further stratify PAH patients classified as intermediate risk by the three-strata model, utilizing Kaplan-Meier survival analysis. The optimal cut-off values for the prognostic IgG Nglycan traits in Kaplan-Meier and Cox regression analyses were determined based on the values that maximized the sum of sensitivity and specificity in ROC analysis.³² Results **Study population and baseline characteristics** The study design is illustrated in Figure 1. A total of 273 patients with PAH enrolled from Fuwai Hospital between 2013 and 2019 (discovery cohort) and 349 patients with PAH enrolled from Shanghai Pulmonary Hospital between 2006 and 2013 (validation cohort) were included in this study.

243

244

245

246

247

248

249

250

251

252

253

254

255

256

257

258

259

260

261

262

263

Among the patients, 58 (21.2%) in the discovery cohort and 109 (31.2%) in the validation cohort were male. The mean ages were 32.8 ± 10.4 and 35.9 ± 16.8 years in the discovery and validation cohorts, respectively. In the discovery cohort, 11 (4.0%) patients received untargeted therapy, 80 (29.3%) patients received monotherapy, 148 (54.2%) patients received dual therapy, and 34 (12.5%) patients received triple therapy. In the validation cohort, 66 (18.9%) patients received untargeted therapy, 227 (65.0%) patients received monotherapy, 53 (15.2%) patients received dual therapy, and 3 (0.9%) patients received triple therapy (Table 1). Follow-up During a median follow-up of 39 (22-63) months, 41 patients (6.6%, 2 in the discovery cohort and 39 in the validation cohort) were lost to follow-up. In total, 139 patients (n = 52 in the discovery cohort and n = 87 in the validation cohort) died at the end of the follow-up periods. Plasma IgG N-glycome profiles in patients with PAH Eight IgG N-glycans were directly detected in our cohorts by matrix-assisted laser desorption/ionization time of flight mass spectrometry. The representative annotated mass spectrometry spectra of the IgG N-glycome profiles from the survivor and nonsurvivor in our PAH cohorts are provided in Supplemental Figure S1, which demonstrates variations in peak patterns between the two groups. As derived N-glycan traits represent glycosylation changes shared by a group of structurally related N-

265

266

267

268

269

270

271

272

273

274

275

276

277

278

279

280

281

282

283

284

285

glycans and enable better interpretation of the biological effects of glycosylation than directly detected N-glycan traits, three derived N-glycan traits including Galactosylation, Bisecting N-acetylglucosamine, and Fucosylation were calculated from the eight directly detected IgG N-glycans. We mainly evaluated IgG derived Nglycan traits in the present study. Identification of prognostic IgG N-glycan traits in patients with PAH Discovery and validation cohorts were used to evaluate the associations of IgG Nglycan traits with the survival of patients. In the discovery cohort, Galactosylation (HR: 2.257, 95% CI: 1.274–4.001, P = 0.005; Figure 2A) and Fucosylation (HR: 0.377, 95% CI: 0.168-0.845, P = 0.018; Figure 2A) were found to predict survival independent of age and sex. Bisecting N-acetylglucosamine had no prognostic value (HR: 0.617, 95% CI: 0.219-1.737, P = 0.361; Figure 2A). We continued to validate our results in the validation cohort. However, only Fucosylation was confirmed to be associated with all-cause death independent of age and sex (HR: 0.264, 95% CI: 0.445-0.751, P = 0.005; Figure 2B) and the prognostic effect of Galactosylation was not replicated (HR: 1.092, 95% CI: 0.694–1.717, *P* = 0.705; Figure 2B). The Bisecting N-acetylglucosamine remained of no prognostic value in the validation cohort (HR: 1.789, 95% CI: 0.554–5.776, P = 0.330; Figure 2B). Finally, IgG Fucosylation was identified as a promising candidate prognostic glycan biomarker, which was further validated below.

287

288

289

290

291

292

293

294

295

296

297

298

299

300

301

302

303

304

305

306

307

The validation of the prognostic value of IgG Fucosylation We further evaluated the prognostic significance of IgG Fucosylation in the combined cohorts. In total, death occurred in 13.1% (25 out of 191) and 29.2% (114 out of 390) of patients in the high and low IgG Fucosylation groups, respectively, resulting in respective 5-year survival rates of 88.5% and 74.6% (P < 0.001 for the log-rank test; Figure 3). To evaluate whether IgG Fucosylation independently impacts the outcome of patients with PAH, Cox regression models were further adjusted for potential confounders including 6MWD, WHO FC, NT-proBNP, RAP, SvO₂, cardiac index, type of PAH, and treatment strategies in addition to age and sex. Our results showed that the low IgG Fucosylation was still significantly associated with a high risk of all-cause death in patients with PAH (HR: 0.490; 95% CI: 0.315-0.763; P = 0.002; Table 2; Figure 4). Furthermore, in order to comprehensively demonstrate the prognostic value of IgG Fucosylation, we further conducted subgroup analyses based on sex and therapeutic strategies. Our results showed that even after stratifying by sex, the association between low IgG Fucosylation and increased all-cause mortality remained robust and there was no significant interaction between sex and IgG Fucosylation (P=0.784; Table 2); Interestingly, low Fucosylation posed a greater risk for males (fully adjusted models; male: HR: 0.387, 95% CI: 0.159-0.941, P = 0.035 and female: HR: 0.527, 95% CI: 0.307-0.906, P = 0.014; Table 2; Figure 4). Furthermore, we did not observe

309

310

311

312

313

314

315

316

317

318

319

320

321

322

323

324

325

326

327

328

329

interactions between IgG Fucosylation and therapeutic strategies (P=0.410; Table 2). We found that IgG Fucosylation continued to independently predict survival within subgroups stratified based on therapeutic strategies (fully adjusted models; dual and triple therapy: HR: 0.376, 95% CI: 0.148-0.954, P = 0.043; treatment naïve and monotherapy: HR: 0.595, 95% CI: 0.354–1, *P* = 0.033; Table 2; Figure 4). At last, we investigated whether the IgG Fucosylation offered improvements in risk prediction in addition to the established prognostic risk equation (three-strata model from the SPAHR and COMPERA analyses)^{30,31} in PAH. We found the addition of IgG Fucosylation to the three-strata model improved the prediction of outcomes from area under the curve (AUC) 0.67 (95%CI: 0.62–0.72) to 0.70 (95%CI: 0.65–0.75) by ROC analysis (P = 0.043 for the difference in AUC) (Figure 5). In addition, about 60% of patients in our cohort met intermediate risk criteria in the tree-strata model (Figure 6A) which was consistent with previous reports, and IgG Fucosylation was useful in further dividing patients in the intermediate risk group into intermediate-high and intermediate-low risk subgroups (P < 0.001, Figure 6B). **Discussion** Risk stratification has become an essential part of the management of patients with PAH. The joint guidelines on pulmonary hypertension released in 2015 by the

European Society of Cardiology (ESC) and the European Respiratory Society (ERS)

introduced a multidimensional risk stratification model integrating 14 variables

331

332

333

334

335

336

337

338

339

340

341

342

343

344

345

346

347

348

349

350

351

obtained from nine distinct assessments. According to this model, the risk is categorized into three strata: low, intermediate, or high. 1,2 However, based on the three-strata model, the majority of patients with PAH were classified as intermediate risk. 30,31 Despite the development of refined or alternative methods, such as the prognostic risk equation from the French,³³ SPAHR,³⁴ REVEAL,³⁵ and COMPERA³⁶ Registries, challenges persist regarding the accuracy of stratification and the consistent availability of various clinical parameters during every patient visit. These limitations underscore the need for improvement in the approach to assessing the risk of PAH. In this context, several researchers have attempted to develop new protein biomarkers/panels from blood samples to improve risk assessment. ³⁷⁻³⁹ Although these studies have made significant contributions to exploring novel biomarkers for PAH, the latest 2022 ESC/ERS guidelines for PAH continued to recommend NTproBNP as the exclusive blood biomarker. 40 Significantly, the studies of glycosylation of plasma proteins as potential biomarkers also shed new light on this field. The roles of plasma IgG N-glycosylation in cardiovascular diseases have been long investigated and discussed. The IgG glycosylation profile was found to be associated with cardiovascular disease risk score and subclinical atherosclerosis. 41 Additionally, alteration in plasma IgG N-glycosylation profiles was reported to be associated with blood pressure status, suggesting that IgG N-glycans may be potential postgenomic biomarkers for hypertension.⁴² Notably, our recent discovery showcased the utility of IgG Gal-ratio, representing the distribution of IgG galactosylation, in evaluating the inflammatory state in patients with chronic thromboembolic pulmonary

353

354

355

356

357

358

359

360

361

362

363

364

365

366

367

368

369

370

371

372

373

hypertension.²⁴ These investigations underscored the immense promise of IgG Nglycans as biomarkers for the identification and prognostication of cardiovascular diseases. However, whether IgG N-glycans can be used as prognostic biomarkers for PAH remains to be explored. To our knowledge, this is the first IgG N-glycomic study in PAH. Applying a robust method based on high-throughput mass spectrometry, we for the first time identified and validated that plasma IgG Fucosylation informs patients' survival independent of established risk factors. We first screened out the promising candidate prognostic marker IgG Fucosylation in the discovery cohort and validated it in another independent cohort. We then demonstrated that low plasma IgG Fucosylation was robustly associated with an increased risk of death in patients with PAH not only through overall analysis adjusted for potential confounders but also through subgroup analyses. At last, we found that the prognostic IgG Fucosylation improved the clinical risk prediction of the established prognostic risk equation (three-strata model from the SPAHR and COMPERA analyses).^{30,31} This study adopted a rigorous validation scheme as used in other biomarker discovery studies, encompassing the stages of discovery (Beijing cohort), validation (Shanghai cohort), and random sampling analysis (combined cohorts). This comprehensive approach provided robust evidence supporting IgG Fucosylation as a significant prognostic factor in PAH, instilling confidence in the reliability of our findings.

375

376

377

378

379

380

381

382

383

384

385

386

387

388

389

390

391

392

393

394

395

Registries worldwide have consistently indicated a higher prevalence but better prognosis among female patients with PAH. 43 Interestingly, in the present study, we also observed sex-related differences and low IgG Fucosylation appeared to pose a higher risk in men compared to that in women. Furthermore, in our subgroup analysis based on therapeutic strategies, our results demonstrated that baseline IgG Fucosylation effectively distinguished low-risk and high-risk patients, not only within the treatment-naïve and monotherapy subgroup but also within the dual and triple therapy subgroup. Despite the substantial advancements in the modern era of PAH treatment, a specific subset of patients continues to face a bleak prognosis. Remarkably, baseline IgG Fucosylation could still discern this subset of patients with adverse outcomes in the context of dual and triple therapy. However, the previously established three-strata model was less effective in predicting outcomes in modern treatment settings compared to monotherapy or treatment-naive subgroups (data not shown). One potential explanation is that the current treatments do not target inflammatory pathways associated with IgG Fucosylation. Although modern dual and triple therapies significantly improve patient survival compared to monotherapy or treatment naïve, this improvement is unrelated to systemic-originated IgG Fucosylation. Baseline IgG Fucosylation can still sensitively predict survival, even more so in the dual and triple therapy groups. These findings suggested IgG Fucosylation may not only be a promising prognostic biomarker but also emerge as a potential novel therapeutic target, distinct from existing targets, for patients with PAH.

397

398

399

400

401

402

403

404

405

406

407

408

409

410

411

412

413

414

415

416

417

In the SPAHR and COMPERA analyses, the majority of patients with PAH were identified as intermediate risk (\sim 60-70%)^{30,31} and similar results were also obtained in our cohorts using the three-strata model they proposed. Identifying high-risk patients is particularly important in the risk assessment at diagnosis. 44,45 Discriminating the intermediate-high risk group from the intermediate risk group that makes up the majority of the patients may prompt physicians to initiate more aggressive initial treatment strategies which have far-reaching effects on patients' long-term survival.⁴⁴ Therefore, a more granular risk stratification is needed for the patients in the intermediate risk group, which is vitally important for therapeutic decisions. Several reports have shown that the use of additional variables improved risk prediction and some groups also proposed the four-strata risk model. ^{36,46-48} In the present study, the potential plasma biomarker IgG Fucosylation also achieved promising results with further discrimination within the intermediate risk group. Specifically, the IgG Fucosylation improved discrimination AUC from 0.67 (uninformative test) to 0.70 (moderately accurate test) and reclassification of patients in the intermediate risk group into intermediate-high and intermediate-low risk of the three-strata model, suggesting IgG Fucosylation provided added values in the risk stratification of PAH in combination with the established clinical targets. Several studies have shown that core fucose on IgG plays a role in the progression of malignant diseases. 49,50 Functional studies revealed that the lack of core fucose in IgG N-glycome greatly increased the proinflammatory capacity of IgG through increased

419

420

421

422

423

424

425

426

427

428

429

430

431

432

433

434

435

436

437

438

439

binding of IgG to FcyRIII and enhanced ADCC. 51,52 Decreased levels of core Fucosylation of IgG N-glycome coincide with increased inflammation in individuals.²⁰ Moreover, in our previous study, we found human plasma IgG Nglycome profiles exhibited a proinflammatory phenotype in chronic thromboembolic pulmonary hypertension and IgG proinflammatory N-glycans may be useful for assessing the occurrence and prognosis of patients with chronic thromboembolic pulmonary hypertension.²⁴ In the present study, decreased levels of IgG Fucosylation were found associated with increased mortality of patients with PAH. Therefore, we speculate that inflammation could be a mediator of the prognostic effect of IgG Fucosylation in patients with PAH, but the potential role of changes in IgG Fucosylation in the development and progression of PAH deserves in-depth exploration in future studies. Circulating BNP or NT-proBNP secreted by cardiac myocytes in response to increased ventricle wall strain⁵³ is the only blood biomarker in the established risk calculators. Besides cardiac-originated BNP or NT-proBNP, systemic-originated IgG Fucosylation which is associated with systemic immune and inflammation was found to provide independent values to inform risk stratification in this study. Therefore, plasma biomarkers from different pathways in the pathophysiology of PAH collectively provide more comprehensive information compared to parameters indicating limited mechanisms. On the other hand, though previous studies have reported some new plasma proteins/protein panels may be useful in the risk

stratification of PAH, IgG Fucosylation identified in the present study is the first glycomic candidate biomarker for PAH prognosis. Glycomic biomarkers have many advantages over other omic markers. Especially, clinical IgG N-glycosylation analysis does not rely as heavily on mild serum/plasma storage conditions and timely analysis (glycans are even stable at 50 °C for two weeks) as many other omics analyses.⁵⁴ It is worth mentioning that the high-throughput workflow for IgG N-glycome profiling applied in the present study has been widely used in various studies, ^{24-27,55} enabling the candidate glycan biomarker to be more convenient for further clinical application. Strengths and limitations A major advantage of this study is that we, for the first time, reliably identified and

440

441

442

443

444

445

446

447

448

449

450

451

452

453

454

455

456

457

458

459

460

461

validated a novel independent prognostic biomarker plasma IgG Fucosylation for PAH using plasma IgG N-glycomics based on relatively large and independent multicenter PAH cohorts with long-term follow-up. Another strength of our study was that the IgG glycan biomarker is systemic-originated and in different pathways of the pathophysiology of PAH from other established risk factors, which provided added values for the prognostication of patients with PAH. Nonetheless, our study has several limitations. First, only idiopathic and heritable PAH were included in our cohorts. The survival in patients with other types of PAH (caused by other associated conditions such as congenital heart disease, connective tissue diseases, and portopulmonary hypertension) may differ significantly from that of patients with idiopathic or heritable PAH. Therefore, applying the conclusions drawn from this

study to other categories of PAH requires extreme caution and the prognostic significance of IgG Fucosylation in other subtypes of PAH will be evaluated in future studies. Second, in the present study, we discovered that decreased levels of IgG Fucosylation were independently associated with an increased risk of death in patients with PAH. Though some functional studies have shown that the absence of core fucose in IgG N-glycome affects inflammatory signaling and immune response outcomes, the mechanisms underlying our findings and the potential role of altered IgG Fucosylation in the development and progression of PAH warrant in-depth investigation. Third, we evaluated the prognostic value of baseline plasma IgG Nglycome profiles in PAH. Future investigations should explore the clinical implications of IgG N-glycome variations in patients undergoing diverse stages of treatment. Last, though the sample size of our cohorts was relatively large, the numbers became small in the subgroups of sensitivity analyses and stratified analyses. The accuracy of IgG Fucosylation in prognostication would be increased with an increased number of samples. **Conclusions**

462

463

464

465

466

467

468

469

470

471

472

473

474

475

476

477

478

479

480

481

482

483

Through a comprehensive scheme, we identified and validated a plasma glycomic prognostic biomarker, which is in different pathophysiological pathways from other established risk factors of PAH, to risk stratify patients with PAH.

Acknowledgements

485

486

487

488

489

490

491

492

493

494

495

496

497

498

499

500

501

502

503

504

505

Supplemental methods

Author Contributions Conception and design: ZCJ, ZJZ, CL, WHW, JLM, and CYC; Analysis and interpretation of data: ZJZ, CL, JLM, YPZ, DL, TYL, JHL, SJZ, JSM, RNL, and LW; Drafting of the manuscript: ZJZ and CL; Critical revision of the manuscript for important intellectual content: ZCJ, JLM, DL, and YPZ; Final approval of the manuscript: all authors; Statistical expertise: KS; Obtaining research funding: ZCJ and ZJZ; Acquisition of data: LC, ZJZ, JHL, WHW, CYC, and DL. **Sources of funding** This work was supported by grants from the National Key Research and Development Program of China (2022YFC2703902 and 2022YFC2703901), the CAMS Innovation Fund for Medical Sciences (2021-I2M-1-018), National Natural Science Foundation of China (82241020 and 32371506), Natural Science Foundation of Shanghai (22ZR1452400), Pujiang Talent Program (22PJD064), and National High-Level Hospital Clinical Research Funding (2022-PUMCH-B-099 and 2022-PUMCH-A-200). **Disclosures** None Supplemental materials

Supplemental Figure S1

References

506

507

508

Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, 1. 509 510 Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines for the diagnosis and treatment of pulmonary hypertension: The Joint Task 511 Force for the Diagnosis and Treatment of Pulmonary Hypertension of the 512 European Society of Cardiology (ESC) and the European Respiratory Society 513 514 (ERS): Endorsed by: Association for European Paediatric and Congenital Cardiology (AEPC), International Society for Heart and Lung Transplantation 515 (ISHLT). Eur Heart J. 2016;37:67-119. doi: 10.1093/eurheartj/ehv317 516 517 2. Galie N, Humbert M, Vachiery JL, Gibbs S, Lang I, Torbicki A, Simonneau G, Peacock A, Vonk Noordegraaf A, Beghetti M, et al. 2015 ESC/ERS Guidelines 518 for the diagnosis and treatment of pulmonary hypertension: The Joint Task 519 520 Force for the Diagnosis and Treatment of Pulmonary Hypertension of the European Society of Cardiology (ESC) and the European Respiratory Society 521 (ERS): Endorsed by: Association for European Paediatric and Congenital 522 Cardiology (AEPC), International Society for Heart and Lung Transplantation 523 (ISHLT). Eur Respir J. 2015;46:903-975. doi: 10.1183/13993003.01032-2015 524 3. Humbert M, Sitbon O, Chaouat A, Bertocchi M, Habib G, Gressin V, Yaici A, 525 Weitzenblum E, Cordier JF, Chabot F, et al. Survival in patients with 526 idiopathic, familial, and anorexigen-associated pulmonary arterial 527

528		hypertension in the modern management era. <i>Circulation</i> . 2010;122:156-163.
529		doi: 10.1161/CIRCULATIONAHA.109.911818
329		doi: 10.1101/CIRCULATIONAHA.109.911818
530	4.	Farber HW, Miller DP, Poms AD, Badesch DB, Frost AE, Muros-Le Rouzic E,
531		Romero AJ, Benton WW, Elliott CG, McGoon MD, et al. Five-Year outcomes
532		of patients enrolled in the REVEAL Registry. Chest. 2015;148:1043-1054.
533		doi: 10.1378/chest.15-0300
534	5.	Benza RL, Miller DP, Barst RJ, Badesch DB, Frost AE, McGoon MD. An
535		evaluation of long-term survival from time of diagnosis in pulmonary arterial
536		hypertension from the REVEAL Registry. Chest. 2012;142:448-456. doi:
537		10.1378/chest.11-1460
538	6.	Pan HM, McClelland RL, Moutchia J, Appleby DH, Fritz JS, Holmes JH,
539		Minhas J, Palevsky HI, Urbanowicz RJ, Kawut SM, et al. Heterogeneity of
540		treatment effects by risk in pulmonary arterial hypertension. Eur Respir J.
541		2023;62. doi: 10.1183/13993003.00190-2023
542	7.	Evans CE, Cober ND, Dai Z, Stewart DJ, Zhao YY. Endothelial cells in the
543		pathogenesis of pulmonary arterial hypertension. Eur Respir J. 2021;58. doi:
544		10.1183/13993003.03957-2020
545	8.	Thenappan T, Ormiston ML, Ryan JJ, Archer SL. Pulmonary arterial
546		hypertension: pathogenesis and clinical management. BMJ. 2018;360:j5492.
547		doi: 10.1136/bmj.j5492
548	9.	Ferrian SP, Cao A, McCaffrey EF, Saito T, Greenwald NF, Nicolls MR, Bruce
549		T, Zamanian RT, Del Rosario P, Rabinovitch M, et al. Single-Cell Imaging

550		Maps Inflammatory Cell Subsets to Pulmonary Arterial Hypertension
551		Vasculopathy. Am J Respir Crit Care Med. 2023. doi: 10.1164/rccm.202209-
552		1761OC
553	10.	Hart GW, Copeland RJ. Glycomics hits the big time. Cell. 2010;143:672-676.
554		doi: 10.1016/j.cell.2010.11.008
555	11.	Ohtsubo K, Marth JD. Glycosylation in cellular mechanisms of health and
556		disease. Cell. 2006;126:855-867. doi: 10.1016/j.cell.2006.08.019
557	12.	Memarian E, Heijmans R, Slieker RC, Sierra A, Gornik O, Beulens JWJ,
558		Hanic M, Elders P, Pascual J, Sijbrands E, et al. IgG N-glycans are associated
559		with prevalent and incident complications of type 2 diabetes. Diabetes Metab
560		Res Rev. 2023;39:e3685. doi: 10.1002/dmrr.3685
561	13.	Varki A. Biological roles of oligosaccharides: all of the theories are correct.
562		Glycobiology. 1993;3:97-130. doi: 10.1093/glycob/3.2.97
563	14.	Schwab I, Nimmerjahn F. Intravenous immunoglobulin therapy: how does IgG
564		modulate the immune system? Nat Rev Immunol. 2013;13:176-189. doi:
565		10.1038/nri3401
566	15.	Arnold JN, Wormald MR, Sim RB, Rudd PM, Dwek RA. The impact of
567		glycosylation on the biological function and structure of human
568		immunoglobulins. Annu Rev Immunol. 2007;25:21-50. doi:
569		10.1146/annurev.immunol.25.022106.141702
570	16.	Simurina M, de Haan N, Vuckovic F, Kennedy NA, Stambuk J, Falck D,
571		Trbojevic-Akmacic I, Clerc F, Razdorov G, Khon A, et al. Glycosylation of

	Immunoglobulin G Associates With Clinical Features of Inflammatory Bowel
	Diseases. Gastroenterology. 2018;154:1320-1333 e1310. doi:
	10.1053/j.gastro.2018.01.002
17.	Jefferis R. Glycosylation as a strategy to improve antibody-based therapeutics.
	Nat Rev Drug Discov. 2009;8:226-234. doi: 10.1038/nrd2804
18.	Pucic M, Knezevic A, Vidic J, Adamczyk B, Novokmet M, Polasek O, Gornik
	O, Supraha-Goreta S, Wormald MR, Redzic I, et al. High throughput isolation
	and glycosylation analysis of IgG-variability and heritability of the IgG
	glycome in three isolated human populations. Mol Cell Proteomics.
	2011;10:M111 010090. doi: 10.1074/mcp.M111.010090
19.	Scanlan CN, Burton DR, Dwek RA. Making autoantibodies safe. Proc Natl
	Acad Sci U S A. 2008;105:4081-4082. doi: 10.1073/pnas.0801192105
20.	Freidin MB, Keser T, Gudelj I, Stambuk J, Vucenovic D, Allegri M, Pavic T,
	Simurina M, Fabiane SM, Lauc G, et al. The Association Between Low Back
	Pain and Composition of IgG Glycome. Sci Rep. 2016;6:26815. doi:
	10.1038/srep26815
21.	Davies J, Jiang L, Pan LZ, LaBarre MJ, Anderson D, Reff M. Expression of
	GnTIII in a recombinant anti-CD20 CHO production cell line: Expression of
	antibodies with altered glycoforms leads to an increase in ADCC through
	higher affinity for FC gamma RIII. Biotechnol Bioeng. 2001;74:288-294.
22.	Mihai S, Nimmerjahn F. The role of Fc receptors and complement in
	autoimmunity. Autoimmun Rev. 2013;12:657-660. doi:

594		10.1016/j.autrev.2012.10.008
595	23.	Karsten CM, Pandey MK, Figge J, Kilchenstein R, Taylor PR, Rosas M,
596		McDonald JU, Orr SJ, Berger M, Petzold D, et al. Anti-inflammatory activity
597		of IgG1 mediated by Fc galactosylation and association of FcgammaRIIB and
598		dectin-1. Nat Med. 2012;18:1401-1406. doi: 10.1038/nm.2862
599	24.	Zhang ZJ, Wang HF, Lian TY, Zhou YP, Xu XQ, Guo F, Wei YP, Li JY, Sun K,
600		Liu C, et al. Human Plasma IgG N-Glycome Profiles Reveal a
601		Proinflammatory Phenotype in Chronic Thromboembolic Pulmonary
602		Hypertension. Hypertension. 2023;80:1929-1939. doi:
603		10.1161/HYPERTENSIONAHA.123.21408
604	25.	Ren S, Zhang Z, Xu C, Guo L, Lu R, Sun Y, Guo J, Qin R, Qin W, Gu J.
605		Distribution of IgG galactosylation as a promising biomarker for cancer
606		screening in multiple cancer types. Cell Res. 2016;26:963-966. doi:
607		10.1038/cr.2016.83
608	26.	Qian Y, Wang Y, Zhang X, Zhou L, Zhang Z, Xu J, Ruan Y, Ren S, Xu C, Gu
609		J. Quantitative analysis of serum IgG galactosylation assists differential
610		diagnosis of ovarian cancer. J Proteome Res. 2013;12:4046-4055. doi:
611		10.1021/pr4003992
612	27.	Zhang Z, Wu J, Liu P, Kang L, Xu X. Diagnostic Potential of Plasma IgG N-
613		glycans in Discriminating Thyroid Cancer from Benign Thyroid Nodules and
614		Healthy Controls. Front Oncol. 2021;11:658223. doi:
615		10.3389/fonc.2021.658223

616	28.	Reiding KR, Blank D, Kuijper DM, Deelder AM, Wuhrer M. High-throughput
617		profiling of protein N-glycosylation by MALDI-TOF-MS employing linkage-
618		specific sialic acid esterification. Anal Chem. 2014;86:5784-5793. doi:
619		10.1021/ac500335t
620	29.	Clerc F, Reiding KR, Jansen BC, Kammeijer GS, Bondt A, Wuhrer M. Human
621		plasma protein N-glycosylation. Glycoconj J. 2016;33:309-343. doi:
622		10.1007/s10719-015-9626-2
623	30.	Kylhammar D, Kjellstrom B, Hjalmarsson C, Jansson K, Nisell M, Soderberg
624		S, Wikstrom G, Radegran G. A comprehensive risk stratification at early
625		follow-up determines prognosis in pulmonary arterial hypertension. Eur Heart
626		J. 2018;39:4175-4181. doi: 10.1093/eurheartj/ehx257
627	31.	Hoeper MM, Kramer T, Pan Z, Eichstaedt CA, Spiesshoefer J, Benjamin N,
628		Olsson KM, Meyer K, Vizza CD, Vonk-Noordegraaf A, et al. Mortality in
629		pulmonary arterial hypertension: prediction by the 2015 European pulmonary
630		hypertension guidelines risk stratification model. Eur Respir J. 2017;50. doi:
631		10.1183/13993003.00740-2017
632	32.	Perkins NJ, Schisterman EF. The Youden Index and the optimal cut-point
633		corrected for measurement error. Biom J. 2005;47:428-441. doi:
634		10.1002/bimj.200410133
635	33.	Boucly A, Weatherald J, Savale L, Jais X, Cottin V, Prevot G, Picard F, de
636		Groote P, Jevnikar M, Bergot E, et al. Risk assessment, prognosis and
637		guideline implementation in pulmonary arterial hypertension. Eur Respir J.

638		2017;50. doi: 10.1183/13993003.00889-2017
639	34.	Kylhammar D, Hjalmarsson C, Hesselstrand R, Jansson K, Kavianipour M,
640		Kjellstrom B, Nisell M, Soderberg S, Radegran G. Predicting mortality during
641		long-term follow-up in pulmonary arterial hypertension. ERJ Open Res.
642		2021;7. doi: 10.1183/23120541.00837-2020
643	35.	Benza RL, Kanwar MK, Raina A, Scott JV, Zhao CL, Selej M, Elliott CG,
644		Farber HW. Development and Validation of an Abridged Version of the
645		REVEAL 2.0 Risk Score Calculator, REVEAL Lite 2, for Use in Patients With
646		Pulmonary Arterial Hypertension. Chest. 2021;159:337-346. doi:
647		10.1016/j.chest.2020.08.2069
648	36.	Hoeper MM, Pausch C, Olsson KM, Huscher D, Pittrow D, Grunig E, Staehler
649		G, Vizza CD, Gall H, Distler O, et al. COMPERA 2.0: a refined four-stratum
650		risk assessment model for pulmonary arterial hypertension. Eur Respir J.
651		2022;60. doi: 10.1183/13993003.02311-2021
652	37.	Rhodes CJ, Wharton J, Ghataorhe P, Watson G, Girerd B, Howard LS, Gibbs
653		JSR, Condliffe R, Elliot CA, Kiely DG, et al. Plasma proteome analysis in
654		patients with pulmonary arterial hypertension: an observational cohort study.
655		Lancet Respir Med. 2017;5:717-726. doi: 10.1016/S2213-2600(17)30161-3
656	38.	Rhodes CJ, Wharton J, Swietlik EM, Harbaum L, Girerd B, Coghlan JG,
657		Lordan J, Church C, Pepke-Zaba J, Toshner M, et al. Using the Plasma
658		Proteome for Risk Stratifying Patients with Pulmonary Arterial Hypertension.
659		Am J Respir Crit Care Med. 2022;205:1102-1111. doi: 10.1164/rccm.202105-

All rights reserved. No reuse allowed without permission.	
---	--

660		1118OC
661	39.	Amsallem M, Sweatt AJ, Arthur Ataam J, Guihaire J, Lecerf F, Lambert M,
662		Ghigna MR, Ali MK, Mao Y, Fadel E, et al. Targeted proteomics of right heart
663		adaptation to pulmonary arterial hypertension. Eur Respir J. 2021;57. doi:
664		10.1183/13993003.02428-2020
665	40.	Humbert M, Kovacs G, Hoeper MM, Badagliacca R, Berger RMF, Brida M,
666		Carlsen J, Coats AJS, Escribano-Subias P, Ferrari P, et al. 2022 ESC/ERS
667		Guidelines for the diagnosis and treatment of pulmonary hypertension. Eur
668		Heart J. 2022;43:3618-3731. doi: 10.1093/eurheartj/ehac237
669	41.	Menni C, Gudelj I, Macdonald-Dunlop E, Mangino M, Zierer J, Besic E, Joshi
670		PK, Trbojevic-Akmacic I, Chowienczyk PJ, Spector TD, et al. Glycosylation
671		Profile of Immunoglobulin G Is Cross-Sectionally Associated With
672		Cardiovascular Disease Risk Score and Subclinical Atherosclerosis in Two
673		Independent Cohorts. Circ Res. 2018;122:1555-1564. doi:
674		10.1161/CIRCRESAHA.117.312174
675	42.	Gao Q, Dolikun M, Stambuk J, Wang H, Zhao F, Yiliham N, Wang Y,
676		Trbojevic-Akmacic I, Zhang J, Fang H, et al. Immunoglobulin G N-Glycans as
677		Potential Postgenomic Biomarkers for Hypertension in the Kazakh Population.
678		OMICS. 2017;21:380-389. doi: 10.1089/omi.2017.0044
679	43.	Cheron C, McBride SA, Antigny F, Girerd B, Chouchana M, Chaumais MC,
680		Jais X, Bertoletti L, Sitbon O, Weatherald J, et al. Sex and gender in
681		pulmonary arterial hypertension. Eur Respir Rev. 2021;30. doi:

682		10.1183/16000617.0330-2020
683	44.	Boucly A, Savale L, Jais X, Bauer F, Bergot E, Bertoletti L, Beurnier A,
684		Bourdin A, Bouvaist H, Bulifon S, et al. Association between Initial Treatment
685		Strategy and Long-Term Survival in Pulmonary Arterial Hypertension. $Am J$
686		Respir Crit Care Med. 2021;204:842-854. doi: 10.1164/rccm.202009-3698OC
687	45.	Galie N, Channick RN, Frantz RP, Grunig E, Jing ZC, Moiseeva O, Preston
688		IR, Pulido T, Safdar Z, Tamura Y, et al. Risk stratification and medical therapy
689		of pulmonary arterial hypertension. Eur Respir J. 2019;53. doi:
690		10.1183/13993003.01889-2018
691	46.	Harbaum L, Fuge J, Kamp JC, Hennigs JK, Simon M, Sinning C, Oqueka T,
692		Grimminger J, Olsson KM, Hoeper MM, et al. Blood carbon dioxide tension
693		and risk in pulmonary arterial hypertension. <i>Int J Cardiol</i> . 2020;318:131-137.
694		doi: 10.1016/j.ijcard.2020.06.069
695	47.	Weatherald J, Boucly A, Chemla D, Savale L, Peng M, Jevnikar M, Jais X,
696		Taniguchi Y, O'Connell C, Parent F, et al. Prognostic Value of Follow-Up
697		Hemodynamic Variables After Initial Management in Pulmonary Arterial
698		Hypertension. Circulation. 2018;137:693-704. doi:
699		10.1161/CIRCULATIONAHA.117.029254
700	48.	Yogeswaran A, Richter MJ, Sommer N, Ghofrani HA, Seeger W, Tello K, Gall
701		H. Advanced risk stratification of intermediate risk group in pulmonary
702		arterial hypertension. Pulm Circ. 2020;10:2045894020961739. doi:
703		10.1177/2045894020961739

- 704 49. Liu S, Cheng L, Fu Y, Liu BF, Liu X. Characterization of IgG N-glycome
- profile in colorectal cancer progression by MALDI-TOF-MS. J Proteomics. 705
- 706 2018;181:225-237. doi: 10.1016/j.jprot.2018.04.026
- 50. Pan H, Wu Z, Zhang H, Zhang J, Liu Y, Li Z, Feng W, Wang G, Liu Y, Zhao 707
- 708 D, et al. Identification and validation of IgG N-glycosylation biomarkers of
- esophageal carcinoma. Front Immunol. 2023;14:981861. doi: 709
- 10.3389/fimmu.2023.981861 710
- Lu J, Chu J, Zou Z, Hamacher NB, Rixon MW, Sun PD. Structure of 711 51.
- 712 FegammaRI in complex with Fc reveals the importance of glycan recognition
- for high-affinity IgG binding. Proc Natl Acad Sci USA. 2015;112:833-838. 713
- doi: 10.1073/pnas.1418812112 714
- 715 52. Shields RL, Lai J, Keck R, O'Connell LY, Hong K, Meng YG, Weikert SH,
- Presta LG. Lack of fucose on human IgG1 N-linked oligosaccharide improves 716
- binding to human Fegamma RIII and antibody-dependent cellular toxicity. J 717
- 718 Biol Chem. 2002;277:26733-26740. doi: 10.1074/jbc.M202069200
- Goetze JP, Bruneau BG, Ramos HR, Ogawa T, de Bold MK, de Bold AJ. 719 53.
- 720 Cardiac natriuretic peptides. *Nat Rev Cardiol*. 2020;17:698-717. doi:
- 10.1038/s41569-020-0381-0 721
- 722 54. Amez Martin M, Wuhrer M, Falck D. Serum and Plasma Immunoglobulin G
- Fc N-Glycosylation Is Stable during Storage. J Proteome Res. 2021;20:2935-723
- 2941. doi: 10.1021/acs.jproteome.1c00148 724
- 55. Qin W, Pei H, Qin R, Zhao R, Han J, Zhang Z, Dong K, Ren S, Gu J. 725

Alteration of Serum IgG Galactosylation as a Potential Biomarker for 726 Diagnosis of Neuroblastoma. J Cancer. 2018;9:906-913. doi: 727 10.7150/jca.22014 728 729

Table 1. Baseline characteristics. 730

	Discovery Cohort (n = 273)	Validation Cohort (n = 349)		
Recruitment period	2013-2020	2006-2013		
Age, y	32.8 ± 10.4	35.9 ± 16.8		
Male, n (%)	58 (21.2)	109 (31.2)		
Ethnic origin	Asian	Asian		
IPAH/HPAH, n (%)	259/14 (94.9/5.1)	338/11 (96.8/3.2)		
WHO FC, n (%)				
I	7 (2.8)	6 (1.8)		
II	103 (41.2)	107 (32.7)		
III	124 (49.6)	199 (60.9)		
IV	16 (6.4)	15 (4.6)		
6MWD, m	416.8 ± 103.0	377.4 ± 116.7		
NT-proBNP, pg/mL	941.0 (230.5–2,212.0)	881.0 (289.0–1,944.0)		
RAP, mm Hg	8.4 ± 6.0	8.0 ± 5.5		
mPAP, mm Hg	58.8 ± 15.6	61.4 ± 14.6		
PAWP, mm Hg	9.5 ± 2.9	8.3 ± 3.3		
PVR, Wood units	13.2 ± 6.1	15.4 ± 7.8		
Cardiac index, L/min/kg/m²	2.5 ± 0.7	2.5 ± 0.9		
Cardiac output, L/min	4.2 ± 1.3	4.0 ± 1.5		
SvO ₂ , %	65.5 ± 9.1	62.4 ± 10.8		
Three-strata risk (I/II/III), n (%)	88/138/30 (33.1/55.6/11.3)	96/206/37 (28.5/60.5/11.0)		
Targeted therapy, n (%)				
Treatment naive	11 (4.0)	66 (18.9)		
Monotherapy	80 (29.3)	227 (65.0)		
Dual therapy	148 (54.2)	53 (15.2)		
Triple therapy	34 (12.5)	3 (0.9)		

⁶MWD = 6-minute walking distance; HPAH = heritable pulmonary arterial 731

hypertension; IPAH = idiopathic pulmonary arterial hypertension; mPAP = mean pulmonary artery pressure; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAWP = pulmonary artery wedge pressure; PVR = pulmonary vascular resistance; RAP= right atrial pressure; SvO_2 = mixed venous oxygen saturation; WHO FC = World Health Organization functional class.

732

733

734

735

Table 2. Results of Cox proportional hazards models examining the relationship between plasma IgG Fucosylation and risk of all-cause death in overall analysis and subgroup analyses according to sex and therapeutic strategies.

	Unadjusted		Fully-adjuste	d	
	HR (95%CI)	P value	HR (95%CI)	P value	P for interaction
Total $(n = 581)$	0.451 (0.292-0.696)	< 0.001	0.490 (0.315-0.763)	0.002	
Sex					0.748
Male $(n = 155)$	0.332 (0.154-0.715)	0.005	0.387 (0.159-0.941)	0.035	
Female $(n = 426)$	0.510 (0.301-0.863)	0.012	0.527 (0.307-0.906)	0.014	
Therapy					0.410
Treatment naïve and monotherapy $(n = 373)$	0.503 (0.304-0.834)	0.008	0.570 (0.340-0.953)	0.032	
Dual and triple therapy $(n = 208)$	0.340 (0.144-0.805)	0.014	0.376 (0.148-0.954)	0.043	

The factors in the fully-adjusted models included age, sex, WHO-FC, 6MWD, NT-proBNP, RAP, SvO₂, PVR, cardiac index, type of PAH, and therapeutic strategies. The factors in the fully-adjusted models included age, sex, WHO-FC, 6MWD, NT-proBNP, RAP, SvO₂, PVR, cardiac index, type of PAH, and therapeutic strategies. 6MWD = 6-minute walking distance; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension. PVR = pulmonary vascular resistance; RAP = right atrial pressure; SvO₂ = mixed venous oxygen saturation; WHO FC = World Health Organization functional class.

Figures

744

745

746

747

748

749




Figure 1. Study design. 6MWD = 6-minute walking distance; NT-proBNP = Nterminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension. PVR = pulmonary vascular resistance; RAP = right atrial pressure; ROC = receiveroperating characteristic; SvO₂ = mixed venous oxygen saturation; WHO FC = World Health Organization functional class.




Figure 2. Hazard ratios and 95% CI from Cox regression analysis evaluating the prognostic IgG N-glycan traits in the discovery and validation cohorts.




Figure 3. Kaplan-Meier survival curve for all-cause death stratified by IgG

Fucosylation in patients with pulmonary artery hypertension. "High Fuc" or "Low 756

757 Fuc" represents IgG Fucosylation higher or lower than 0.9741.

754




Figure 4. Hazard ratios and 95% CI from Cox regression analysis evaluating the IgG Fucosylation in combined cohorts and subgroup analyses (A) without adjustment, and (B) with full adjustment. The factors in the fully-adjusted models included age, sex, WHO-FC, 6MWD, NT-proBNP, RAP, SvO₂, PVR, cardiac index, type of PAH, and therapeutic strategies. 6MWD = 6-minute walking distance; NT-proBNP = N-terminal pro-B-type natriuretic peptide; PAH = pulmonary arterial hypertension. PVR = pulmonary vascular resistance; RAP = right atrial pressure; SvO₂ = mixed venous oxygen saturation; WHO FC = World Health Organization functional class.




Figure 5. The performance of the established three-strata model (from the SPAHR and COMPERA analyses) before and after the addition of IgG Fucosylation evaluated by receiver-operating characteristic analysis. AUC = area under the curve.

765

766




Figure 6. Kaplan-Meier survival curve for all-cause death stratified by the established three-strata model (from the SPAHR and COMPERA analyses) (A) before and (B) after the addition of IgG Fucosylation in patients with pulmonary artery hypertension.